Fisher Wallace Laboratories
Fisher Wallace Laboratories is a privately held Brooklyn-based medical device company selling prescription wearable transcranial alternating current stimulation (tACS) devices for anxiety, depression, and insomnia, with a next-generation population-scale OAK device pending FDA clearance in Q3 2026.
- Company typePrivate
- Founded2009
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Fisher Wallace Laboratories does
Fisher Wallace Laboratories, Inc. is a privately held Brooklyn, New York–based medical device company (founded 2009; 1-10 employees) that develops and sells prescription wearable brain stimulation devices for treating neuropsychiatric conditions including anxiety, depression, insomnia, bipolar II depression, and symptoms of Parkinson's disease. Its core technology is transcranial alternating current stimulation (tACS), a non-invasive modality that entrains neural oscillations and induces synaptic plasticity; nearly 2,000 participants have been enrolled across the company's clinical studies, and Harvard Medical School / Massachusetts General Hospital researchers have modeled the technology's engagement of brain structures governing mood, sleep, autonomic function, and cognitive resilience.
The company's commercial product base consists of the FDA-cleared Version 1.0 proof-of-concept device (over 70,000 units sold since 2010, distributed through thousands of prescribers) plus a line of replacement accessories (sponges, headbands, lead wires, receptacles, carrying case). Its next-generation OAK device — developed in collaboration with the team behind Beats and Nest and designed for population-scale deployment — anticipates initial FDA clearance for anxiety in Q3 2026 and additional indications (insomnia, depression, human performance) in 2027, with a first manufacturing run of 10,000 units. The OAK device is currently being pilot tested within the U.S. Department of Veterans Affairs.
Fisher Wallace generates revenue primarily through direct-to-consumer e-commerce sales of its prescription device and accessories on fisherwallace.com, and it has been a notable user of SEC-regulated equity crowdfunding — having raised more than $11 million from early adopters via StartEngine and its own platform — with an institutional $2.5 million round led by SHUFL Capital in April 2022. Key customer segments include individual patients with neuropsychiatric conditions, first responders (evidenced by a 164-participant study with the Seattle Police Department and Washington State University), and military veterans (via the VA pilot), supported by an advisory bench drawn from Mass General Brigham, Harvard Medical School, and former VA leadership.
Fisher Wallace Laboratories firmographics
Firmographics- Name
- Fisher Wallace Laboratories
- Legal name
- Fisher Wallace Laboratories, Inc.
- Website
- https://fisherwallace.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Fisher Wallace Laboratories is a privately held Brooklyn-based medical device company selling prescription wearable transcranial alternating current stimulation (tACS) devices for anxiety, depression, and insomnia, with a next-generation population-scale OAK device pending FDA clearance in Q3 2026.
- Ownership category
- akta.pro rank
Fisher Wallace Laboratories industry classification
Industry- Product category
- Wearable Neurostimulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL)
- akta.pro secondary industries
- Sleep Tech Wearables (CRACAIAG), Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
Keywords
Where Fisher Wallace Laboratories is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Fisher Wallace Laboratories business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Prescription Wearable Device Sales: Sale of FDA-cleared brain stimulation devices directly to patients with prescriptions. The company has sold over 70,000 units of its proof-of-concept device.
- Accessories and Consumables: Sale of replacement accessories including sponges, headbands, lead wires, and carrying cases for the Version 1.0 device.
- Equity Crowdfunding: SEC-regulated equity crowdfunding campaigns raising capital from early adopters and retail investors. Over $11 million raised collectively through these campaigns.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Accessories and replacement parts for Version 1.0 device |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Fisher Wallace Laboratories product offering
Product offeringCore offering
Fisher Wallace Laboratories designs, manufactures, and sells prescription wearable brain stimulation devices using Transcranial Alternating Current Stimulation (tACS) for the treatment of anxiety, depression, and insomnia. Its currently commercial device, Version 1.0, is FDA-cleared, with over 70,000 units sold; the next-generation OAK device is in development pending initial FDA clearance anticipated in Q3 2026. The company also sells replacement accessories — sponges, headbands, lead wires, receptacles, and carrying cases — to support its installed base.
Product overview
Fisher Wallace Laboratories offers prescription wearable brain stimulation devices for treating neuropsychiatric disorders. The portfolio consists of two main products: the original Version 1.0 proof-of-concept device (FDA-cleared for anxiety, depression, and insomnia, with over 70,000 units sold since 2010) and the next-generation OAK device (anticipating FDA clearance in Q3 2026). Both products use Transcranial Alternating Current Stimulation (tACS) technology. The product line is supported by a range of accessories including replacement sponges, headbands, lead wires, electrode receptacles, and carrying cases.
Differentiator
Problem solved
Functional benefit
Brands
- OAK: Next-generation prescription brain stimulation device designed for population-scale, the result of 17 years of clinical research and product development in collaboration with the team behind Beats and Nest. Anticipated initial FDA clearance for anxiety treatment in Q3 2026.
- Version 1.0
Products and services
- OAK Brain Stimulation Device Prescription wearable brain stimulation device using Transcranial Alternating Current Stimulation (tACS) to treat anxiety at population scale, with anticipated FDA clearance for anxiety in Q3 2026 and follow-on indications for insomnia, depression, and human performance in 2027.
- Fisher Wallace Version 1.0 Brain Stimulation Device FDA-cleared wearable brain stimulation device using Transcranial Alternating Current Stimulation (tACS) to treat anxiety, depression, and insomnia in adults, distributed to more than 70,000 patients through a prescriber channel.
- Extra Fisher Wallace Sponges (48 pack) Replacement electrode sponges packaged in a 48-count supply (approximately 6 months) intended for Version 1.0 device users, with recommended replacement every two weeks.
- Replacement Velcro Headband Adjustable replacement Velcro headband used to secure electrode placement during Version 1.0 brain stimulation treatment sessions.
- Replacement Black Lead Wire Replacement black lead wire that connects the Version 1.0 brain stimulation device to the headband electrodes.
- Replacement Red Lead Wire Replacement red lead wire that connects the Version 1.0 brain stimulation device to the headband electrodes.
- Replacement Sponge Receptacles Replacement electrode receptacles that hold sponges on the Version 1.0 brain stimulation device during treatment sessions.
- Fisher Wallace Pouch Carry case designed for storing and transporting the Fisher Wallace brain stimulation device and its accessories.
Quantifiable outcome
- Rapid anxiety symptom reduction that continued improving over eight-week study period in 164 first responders
- +3 more outcomes
Companies that use Fisher Wallace Laboratories
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Fisher Wallace Laboratories technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Fisher Wallace Laboratories partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered major and core.
- Harvard Medical SchoolmajorResearchers at Harvard Medical School modeled the strength of the company's neurostimulation in the brain, demonstrating significant engagement of structures governing mood, sleep, autonomic function, and cognitive resilience in 2025 research.
- Massachusetts General HospitalmajorCollaborated with Fisher Wallace on clinical research demonstrating device effectiveness and safety. Home to key advisor Maurizio Fava, MD, Chair of Department of Psychiatry at Mass General Brigham.
- U.S. Department of Veterans AffairsmajorCompany's next-generation technology OAK is currently being pilot tested in the U.S. Department of Veterans Affairs. Advisory board includes Ninth Secretary of Veterans Affairs David Shulkin.
- Seattle Police DepartmentcoreCollaborated in real-world study of 164 first responders demonstrating rapid anxiety symptom reduction over eight-week study period as part of FDA clearance application.
- Washington State UniversitycorePartnered with company and other first responder organizations for the clinical study supporting FDA clearance application.
Scale indicators7 records
Recent moves8 records
Expansion highlights5 records
Fisher Wallace Laboratories competitors and assessment
Company assessmentDirect peers
- Alpha-Stim (Electromedical Products): Alpha-Stim manufactures FDA-cleared cranial electrotherapy stimulation (CES) devices for anxiety, insomnia, and depression. It is the most direct competitor to Fisher Wallace in non-invasive electrotherapeutic brain stimulation for mental health, serving overlapping patient populations and prescriber channels.
- Neuronetics: Neuronetics markets NeuroStar, a transcranial magnetic stimulation (TMS) system for major depressive disorder. It competes for the same prescriber relationships and depression patient population as Fisher Wallace, offering an alternative non-invasive brain stimulation modality.
- Brainsway: Brainsway develops deep transcranial magnetic stimulation (Deep TMS) systems for depression, OCD, and other psychiatric conditions. It is a comparable non-pharmaceutical, non-invasive neuromodulation company serving similar patient populations and prescriber markets as Fisher Wallace.
- NeuroSigma: NeuroSigma markets the Monarch eTNS system, a non-invasive external trigeminal nerve stimulation device cleared by FDA for ADHD and depression. It is a direct competitor in the prescription non-invasive brain stimulation category targeting neuropsychiatric conditions.
Broad incumbents
- Magstim: Magstim is an established manufacturer of TMS stimulators and coils used in clinical research and depression treatment. It serves the same transcranial stimulation clinical and research market as Fisher Wallace, with a broader neurology-focused product portfolio.
Emerging players
- Apollo Neuroscience: Apollo Neuroscience offers a consumer wearable that delivers gentle vibrations to influence the nervous system for stress, sleep, and focus. While it uses a different mechanism (vibrotactile vs. electrical stimulation), it competes for the same mental wellness consumer and prescriber attention.
- Halo Neuroscience: Halo Neuroscience developed transcranial direct current stimulation (tDCS) headbands initially for athletic performance. It is an emerging non-invasive neurostimulation company with overlapping technology category (electrical brain stimulation) and partial overlap in mental performance applications.
- Cerebral: Cerebral is a tele-mental-health company prescribing and managing treatment for anxiety, depression, and insomnia. It represents a partial overlap through shared patient population and prescriber relationships, though Cerebral focuses on pharmaceutical rather than device-based treatment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Fisher Wallace Laboratories social profiles
Digital presenceFisher Wallace Laboratories compliance and trust
Trust signalCompliance1 record
Fisher Wallace Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fisher Wallace Laboratories leadership team
Management profileNumber of profiles
Profiles5 records
Fisher Wallace Laboratories funding detail
Funding detailFunding overview
Funding rounds15 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fisher Wallace Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fisher Wallace Laboratories
What does Fisher Wallace Laboratories do?
Fisher Wallace Laboratories designs, manufactures, and sells prescription wearable brain stimulation devices using Transcranial Alternating Current Stimulation (tACS) for the treatment of anxiety, depression, and insomnia. Its currently commercial device, Version 1.0, is FDA-cleared, with over 70,000 units sold; the next-generation OAK device is in development pending initial FDA clearance anticipated in Q3 2026. The company also sells replacement accessories — sponges, headbands, lead wires, receptacles, and carrying cases — to support its installed base.
Is Fisher Wallace Laboratories a public or private company?
Fisher Wallace Laboratories is a private company. It is classified as venture growth investor backed and is currently operating.
When was Fisher Wallace Laboratories founded?
Fisher Wallace Laboratories was founded in 2009. It employs 1 to 10 people.
Where is Fisher Wallace Laboratories based?
Fisher Wallace Laboratories is headquartered in New York, United States, in the North America region.
How does Fisher Wallace Laboratories make money?
Three revenue lines are on record. Prescription Wearable Device Sales are the primary driver. The others are accessories and Consumables and equity Crowdfunding.
Who are Fisher Wallace Laboratories's main competitors?
Direct peers on record are Alpha-Stim (Electromedical Products), Neuronetics, Brainsway and NeuroSigma. Magstim is listed as a broad incumbent. Emerging players are Apollo Neuroscience, Halo Neuroscience and Cerebral.
Does Fisher Wallace Laboratories have an API?
No public API is recorded for Fisher Wallace Laboratories.
What industry is Fisher Wallace Laboratories in?
Fisher Wallace Laboratories's product category is Wearable Neurostimulation Devices. Its primary akta.pro industry code is CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices), with a secondary code of CRACAIAG, Sleep Tech Wearables. Its NAICS code is 334510 and its SIC code is 3845.